浸润性小叶癌眼眶转移一例罕见病例:18F-FDG PET/CT的挑战与影像学共识的探索
一例74岁无癌症病史且规律接受乳腺X线检查的女性因视觉症状就诊,发现浸润性小叶癌眼眶转移;因MRI禁忌行18F-FDG PET/CT,显示右眼眶轻度高代谢肿块及左乳晕下低摄取。小样本研究提示16α-18F-氟雌二醇和成纤维细胞活化蛋白抑制剂在浸润性小叶癌中摄取高于18F-FDG,目前该亚型影像检查尚无共识。
要点
- 浸润性小叶癌可表现为眼眶转移,18F-FDG PET/CT上仅呈轻度高代谢。
- 乳腺X线对浸润性小叶癌的假阴性率高于其他乳腺癌,易致分期不准。
- 小样本研究提示18F-氟雌二醇PET/CT及成纤维细胞活化蛋白抑制剂在浸润性小叶癌中摄取高于18F-FDG。
核心结论
- 本病例提示18F-氟雌二醇PET/CT和成纤维细胞活化蛋白抑制剂在浸润性小叶癌中可能优于18F-FDG。
研究设计与样本
- 病例报告,1例74岁女性,因MRI禁忌行18F-FDG PET/CT检查。
关键影像表现/征象
- 18F-FDG PET/CT显示右眼眶肿块呈轻度高代谢。
- 左乳晕下乳腺组织呈低摄取,提示浸润性小叶癌转移。
临床应用与阅片要点
- 作者提供此病例以突出18F-氟雌二醇PET/CT和成纤维细胞活化蛋白抑制剂在该乳腺癌亚型中相对于18F-FDG的潜在优势。
局限性
- 目前浸润性小叶癌的影像检查尚无共识。
- 乳腺X线对浸润性小叶癌的假阴性率高于其他乳腺癌,使该患者人群更易出现分期不准确和肿瘤负荷评估错误。
- 小样本研究发现浸润性小叶癌中16α-18F-氟雌二醇和成纤维细胞活化蛋白抑制剂摄取高于18F-FDG。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Invasive lobular carcinoma (ILC) frequently underlies orbital metastasis. A 74-y-old woman, who was current with mammograms and had no cancer history, presented to her ophthalmologist with visual complaints and was found to have metastatic ILC. MRI was contraindicated, and an 18F-FDG PET/CT scan revealed a mildly hypermetabolic right orbital mass and low uptake in the left subareolar breast, suggestive of metastatic ILC. Small studies have found that in ILC, 16α-18F-fluoroestradiol and fibroblast activation protein inhibitors are more avid than 18F-FDG. There is currently no consensus regarding imaging for ILC. Many people have contraindications to MRI, and the higher rate of false-negative findings on mammography for ILC than for other breast cancers makes this patient population more vulnerable to inaccurate staging, incorrect assessment of tumor burden, and, consequently, insufficient treatment. We provide this interesting case to highlight the potential of 18F-fluoroestradiol PET/CT and fibroblast activation protein inhibitors over 18F-FDG in this breast cancer subtype.
引用
- Lam M, Yang J, Vijayakumar V, et al. A Rare Case of Orbital Metastasis from Invasive Lobular Carcinoma: Challenges of 18F-FDG PET/CT and the Search for Consensus on Imaging. J Nucl Med Technol. 2024. PMID: 39438056. doi:10.2967/jnmt.124.267732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。